A phase II study of percutaneous radiofrequency ablation for malignant reanl tumor (JIVROSG-0701)

Phase 1

• Conditions: malignant renal tumor

• Registration Number: JPRN-UMIN000001123
• Lead Sponsor: Japan Interventional Radiology in Oncology Study Group (JIVROSG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-04-22
• Study Completion: 2010-08-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

Not provided

Exclusion Criteria

1) Cardiac pacemaker. 2) Artery, nerve or ureter exists on the puncture route. 3) Target lesion adjacent to renal pelvis, or a RFA needle can not be inserted without passing through renal pelvis or alimentary tract. 4) Non-mesurable target lesion on CT. 5) Colinically significant bleeding tendency or abnormal coagulation. 6) Tentative stop of anti-platelet or anti-coagulant medication is not allowed. 7) Drug allergy 8) With active infection 9) With active inflammation 10) Fever above 38 degrees Celsius. 11) If having multiple lesions, no treatment of tumors except a target lesion for 4 weeks after the treatment for a target lesion is not allowed. 12) Stop of chemotherapy or immunotherapy for 4 weeks after the treatment for a target lesion is not allowed. 13) Previous reginal therapy for the target lesion. 14) Pregnancy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adverse events

Secondary Outcome Measures

Name	Time	Method
Response rate of tumor shrinkage on RECIST